HCW Biologics Inc. (HCWB)
Automate Your Wheel Strategy on HCWB
With Tiblio's Option Bot, you can configure your own wheel strategy including HCWB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HCWB
- Rev/Share 0.4679
- Book/Share -0.0292
- PB -138.0331
- Debt/Equity -123.5512
- CurrentRatio 0.1079
- ROIC -1.4473
- MktCap 8670976.0
- FreeCF/Share -7.1389
- PFCF -0.6823
- PE -0.3328
- Debt/Assets 0.2221
- DivYield 0
- ROE 3.4005
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Watch the "What This Means" video here
Read More
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. (“Wugen”) on its recently announced $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling …
Read More
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.
Read More
About HCW Biologics Inc. (HCWB)
- IPO Date 2021-07-20
- Website https://www.hcwbiologics.com
- Industry Biotechnology
- CEO Hing C. Wong
- Employees 36